Charles  Bennett  to  Platelet Aggregation Inhibitors
                            
                            
                                This is a "connection" page, showing publications  Charles  Bennett  has written about  Platelet Aggregation Inhibitors.
                            
                            
                            
                                
                                    
                                            
    
        
        
        
            Connection Strength
            
                
            
            1.963
         
        
        
     
 
    
        
        - 
            Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost. 2012 Nov; 38(8):845-53.
            
            
                Score: 0.338
             
- 
            Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008). Kidney Int Suppl. 2009 Feb; (112):S20-4.
            
            
                Score: 0.261
             
- 
            Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project. J Am Coll Cardiol. 2007 Sep 18; 50(12):1138-43.
            
            
                Score: 0.236
             
- 
            Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration. Stroke. 2004 Feb; 35(2):533-7.
            
            
                Score: 0.183
             
- 
            Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med. 2000 Jun 15; 342(24):1773-7.
            
            
                Score: 0.143
             
- 
            Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention. Arch Intern Med. 1999 Nov 22; 159(21):2524-8.
            
            
                Score: 0.138
             
- 
            Ticlopidine and TTP after coronary stenting. JAMA. 1999 Nov 10; 282(18):1717; author reply 1718-9.
            
            
                Score: 0.138
             
- 
            Major hemorrhage in chronic lymphocytic leukemia patients in the US Veterans Health Administration system in the pre-ibrutinib era: Incidence and risk factors. Cancer Med. 2019 05; 8(5):2233-2240.
            
            
                Score: 0.132
             
- 
            Cost-effectiveness model of a phase II clinical trial of a new pharmaceutical for essential thrombocythemia: is it helpful to policy makers? Semin Hematol. 1999 Jan; 36(1 Suppl 2):26-9.
            
            
                Score: 0.130
             
- 
            Thrombotic thrombocytopenic purpura after stenting and ticlopidine. Lancet. 1998 Sep 26; 352(9133):1036-7.
            
            
                Score: 0.127
             
- 
            Thrombotic thrombocytopenic purpura associated with ticlopidine. A review of 60 cases. Ann Intern Med. 1998 Apr 01; 128(7):541-4.
            
            
                Score: 0.123
             
- 
            Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA. 2007 May 09; 297(18):1992-2000.
            
            
                Score: 0.014